Cisplatin is among the most active chemotherapeutic agents available today for the treatment of a variety of cancers. Toxic side‐effects have up until now prevented dose escalation and schedule intensification which might be interesting in view of the dose‐response relationship and the schedule‐response relationship.Recent developments in supportive care and pharmacology limited these side‐effects and thereby rendered dose‐intensification feasible.Currently, we have treated 71 patients with high‐dose cisplatin administered in hypertonic saline weekly for 6 weeks. Most cycles were supported by 5HT3antagonists to achieve maximal anti‐emetic control. The patients participated in a phase I study (MTD 85 mg/m2) or phase II studies (80 mg/m2) in head and neck cancer/mesothelioma/non‐small cell lung carcinoma or a pilot study of cisplatin weekly in combination with etoposide orally(MTD 70mg CDDP/m2dl + 8 + 15 etoposide50mg/dd p.o. dl‐15 qd282 cycles). The phase II studies are ongoing.The major problem associated with this treatment schedule was myelosuppression. Less frequently observed side‐effects were: nausea/vomiting, nephrotoxicity, anorexia, neuro‐ and ototoxicity. Besides, the weekly treatment schedule has an impact on the patient's quality of life due to frequent hospitalizations. In order to optimize the care of these patients, continuity of care was provided by a process plan. Optimal patient information and education improved patient motivation and compliance with this regime.This paper will present information on this process plan and the nursing implic